Parent drug is transiently bound to a TransCon linker-soluble carrier moiety, which inactivates and shields the parent drug from clearance.

Following injection, the linker is designed to auto-hydrolyze at specific rates to predictably release unmodified parent drug.

Slow release of parent drug acts like an endogenous compound; the linker-carrier is then cleared renally.

Predictable release of unmodified parent drug supports dosing frequency from daily to up to six months or more

Enables sustained localized or systemic drug exposure

Reduces dosing frequency to improve patient adherence and overall treatment outcomes

Same mode of action as parent drug

Same established safety profile as parent drug with potential enhancements or improvements due to application of TransCon technologies

Comparable alternative to continuous infusions or subcutaneous injections

Product Invention Patent

Exclusive license to develop and commercialize Ascendis Pharma's endocrinology therapies in Greater China